Deleting klotho in mice compresses lifespan. Overexpressing it extends lifespan. Very few single genes do both that cleanly - which is why klotho became one of the most hyped proteins in longevity. Here is what survives contact with the human evidence.
Klotho was found by accident in the 1990s. A transgenic mouse line disrupted a gene the researchers were not targeting, and the resulting animals aged in fast-forward: shortened lifespan, arteriosclerosis, ectopic calcification, osteoporosis, skin atrophy, emphysema, and infertility. The gene was named for Klotho, the Fate who spins the thread of life.
The reverse experiment is what made the field pay attention. Overexpressing klotho in mice extended lifespan. A gene where loss compresses lifespan and gain extends it is rare, and it moved klotho out of the ordinary catalogue of ageing-associated genes into a much shorter list of candidate regulators.
There are three family members - alpha, beta and gamma - and they are not interchangeable. Beta-klotho is the co-receptor for FGF21 and belongs to metabolic signalling. Alpha-klotho is the one tied to the ageing phenotype, and it is what people mean when they say “klotho.”
Alpha-klotho does two structurally different things, and conflating them causes most of the confusion in popular coverage.
It partners with FGF receptors to give them specificity for fibroblast growth factor 23 (FGF23), a bone-derived hormone that instructs the kidney to excrete phosphate and to reduce active vitamin D production. Without klotho, FGF23 cannot signal properly, phosphate is retained, and widespread soft-tissue calcification follows. A substantial part of what looks like accelerated ageing in the klotho-deficient mouse is, mechanistically, a disorder of phosphate handling.
The extracellular domain is cleaved and released into blood, cerebrospinal fluid and urine, where it acts independently of FGF23. Reported activities include modulation of insulin and IGF-1 signalling, inhibition of Wnt signalling, effects on TGF-beta and oxidative stress pathways, and regulation of ion transporters at the cell surface. This soluble form is what circulating assays measure and what the cognition literature is largely about.
Expression is concentrated in the kidney, then the choroid plexus and parathyroid. It is not a systemically abundant protein - part of why the circulating pool is hard to raise, and why kidney health dominates the human numbers.
The most-cited human evidence involves a haplotype called KL-VS, defined by two amino acid substitutions in the klotho gene.
Across several cohorts, people carrying one copy have shown associations with better cognitive performance, larger volume in some brain regions, and in some analyses more favourable cardiovascular measures. Carriers make up a meaningful share of the population, so this is not a rare-variant curiosity.
The detail that undercuts the supplement pitch: people with two copies generally do not show the advantage, and in several analyses trend the other way. If the klotho-cognition relationship were a simple dose-response, two copies should beat one. They do not. That points to an optimum rather than a maximum - a poor foundation for any product promising to push klotho as high as possible.
The associations are also not uniformly replicated. Several well-powered cohorts failed to reproduce the cognitive effect, and effect sizes where found are modest. The reported interaction where KL-VS heterozygosity may partially offset APOE4-associated risk is biologically provocative but has not been consistent enough to act on.
Circulating alpha-klotho can be measured and it declines with age. It also falls steeply in chronic kidney disease, often early, which is why it attracted interest as a CKD biomarker. Three problems make consumer-facing klotho testing largely uninterpretable today.
Assay disagreement. Different ELISA kits produce different absolute values and correlate imperfectly. A number from one lab is not comparable to a number from another.
No established reference range. There is no consensus normal or actionable threshold for a healthy adult, so a result cannot be acted on the way an LDL or HbA1c can.
Kidney confounding. Because renal expression dominates, low klotho frequently reflects reduced kidney function. If kidney function is the real driver of an outcome, klotho is a marker riding along rather than an independent target.
This is the central interpretive trap in the field. Klotho correlates with things that matter, but much of that correlation runs through kidney function and age. Showing that raising klotho causes better human outcomes is a far harder claim than showing that low klotho travels with bad ones.
You cannot take klotho orally. It is a large glycoprotein; swallowed, it is digested. Any product marketed as a “klotho supplement” is either not klotho, or is not delivering it intact into circulation.
Exercise has the most consistent human association. Cross-sectional and interventional studies report higher circulating alpha-klotho with greater physical activity and with structured aerobic training. Effect sizes are modest and study quality varies, but the direction is consistent - and the intervention is worth doing regardless of whether klotho is doing the work.
Kidney protection is the most defensible indirect lever: blood pressure control, glycaemic control, avoiding nephrotoxic exposures, and not carrying an unnecessary phosphate load. It protects the organ producing most of the circulating pool.
Pharmacological candidates appear in the literature - certain renin-angiotensin agents, PPAR-gamma agonists and vitamin D signalling have all been reported to influence klotho expression - but these are observations in disease populations and animal models, not established klotho-raising therapies for healthy people.
Gene therapy and recombinant protein is where the serious translational work sits, including cognitive findings in animal models that attracted significant attention. That is genuinely promising early-stage science, several long steps from a human therapy, and with no relationship at all to anything currently for sale.
An honest position: follow klotho as a research story worth watching, particularly the recombinant protein and vector work. Do not buy anything on the strength of it. If a product claims to raise your klotho, ask for human data showing measured circulating alpha-klotho rising - and expect not to receive it.
No. Klotho is a large glycoprotein and is not orally bioavailable - swallowed, it is broken down like any other dietary protein. Products marketed as klotho supplements or boosters are blends of other ingredients with claimed indirect effects, and none have human data showing they meaningfully raise measured circulating alpha-klotho.
KL-VS is a klotho haplotype defined by two amino acid substitutions. One copy has been associated with better cognitive measures in several cohorts; two copies generally lose that advantage. Testing is not clinically useful - the associations are modest, inconsistently replicated, and no intervention changes based on the result.
Unresolved. Klotho is concentrated in the kidney and falls with both age and chronic kidney disease, so low circulating klotho often reflects declining renal function rather than independently driving other outcomes. The mouse work is genuinely causal in that model; whether raising klotho in humans improves outcomes has not been demonstrated.
Not for healthy people. Different assay kits give different absolute values and correlate imperfectly, there is no consensus reference range, and no threshold triggers a specific action. Its main current use is in kidney disease research.
Exercise has the most consistent human association, with modest effect sizes. Beyond that, protecting kidney function through blood pressure and glucose control is the most defensible indirect approach, since the kidney produces most of the circulating pool.
A 28-day fillable sleep log built around the seven levers that actually move sleep, so you test one per week and see what it did.
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.